BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BMRN
  • CUSIP: 09061G10
  • Web: www.bmrn.com
Capitalization:
  • Market Cap: $15.56451 billion
  • Outstanding Shares: 174,490,000
Average Prices:
  • 50 Day Moving Avg: $90.58
  • 200 Day Moving Avg: $90.00
  • 52 Week Range: $78.42 - $102.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -242.56
  • P/E Growth: -2.27
Sales & Book Value:
  • Annual Revenue: $1.18 billion
  • Price / Sales: 12.91
  • Book Value: $15.98 per share
  • Price / Book: 5.46
Profitability:
  • EBIDTA: ($99,850,000.00)
  • Net Margins: -48.43%
  • Return on Equity: -22.71%
  • Return on Assets: -15.40%
Debt:
  • Debt-to-Equity Ratio: 0.24%
  • Current Ratio: 3.98%
  • Quick Ratio: 2.85%
Misc:
  • Average Volume: 1.27 million shs.
  • Beta: 1.85
  • Short Ratio: 5.73
 
Frequently Asked Questions for BioMarin Pharmaceutical (NASDAQ:BMRN)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings data on Thursday, May, 4th. The company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.33. The firm earned $303.70 million during the quarter, compared to analyst estimates of $292.58 million. BioMarin Pharmaceutical had a negative return on equity of 22.71% and a negative net margin of 48.43%. The business's quarterly revenue was up 28.3% on a year-over-year basis. During the same period last year, the company posted ($0.53) EPS. View BioMarin Pharmaceutical's Earnings History.

When will BioMarin Pharmaceutical make its next earnings announcement?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for BioMarin Pharmaceutical.

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2017?

21 equities research analysts have issued 12-month target prices for BioMarin Pharmaceutical's stock. Their forecasts range from $84.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $112.05 in the next twelve months. View Analyst Ratings for BioMarin Pharmaceutical.

What are analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "BioMarin’s orphan disease drugs – Vimizim and Kuvan – are doing well, backed by strong underlying patient demand trends. BioMarin should continue to see growth in both the drugs in 2017, driven by robust patient growth and penetration.  Brineura’s FDA and EU approval was a huge boost. Pipeline development is also on track with significant upcoming pipeline news flow. However, BioMarin has suffered few regulatory setbacks related to its pipeline candidates in the past. Delayed approvals or further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due infrequent ordering patterns from some countries. Meanwhile, the stock underperformed the broader industry this year so far. Loss estimates have remained stable ahead of the company’s Q2 earnings result. However, BioMarin has a positive record of earnings surprises in the recent quarters." (7/19/2017)
  • 2. Cowen and Company analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
  • 5. J P Morgan Chase & Co analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

  • Jean-Jacques Bienaime, Chairman of the Board, Chief Executive Officer
  • Daniel Keith Spiegelman, Chief Financial Officer, Executive Vice President
  • G. Eric Davis, Executive Vice President, General Counsel, Secretary
  • Jeff Robert Ajer, Executive Vice President, Chief Commercial Officer
  • Robert A. Baffi Ph.D., Executive Vice President - Technical Operations
  • Henry J. Fuchs M.D.,Ph.D., Executive Vice President and Chief Medical Officer
  • Brian R. Mueller, Group Vice President, Corporate Controller, Chief Accounting Officer
  • Richard A. Meier, Lead Independent Director
  • Willard H. Dere M.D., Independent Director
  • Michael G. Grey, Independent Director

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Manning & Napier Advisors LLC (1.21%), Strs Ohio (0.35%), AMF Pensionsforsakring AB (0.15%), National Pension Service (0.09%), Great West Life Assurance Co. Can (0.08%) and Bank of Montreal Can (0.05%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Bank of Montreal Can, Strs Ohio, Creative Planning, Tokio Marine Asset Management Co. Ltd., Sumitomo Mitsui Asset Management Company LTD, Janney Montgomery Scott LLC and DnB Asset Management AS. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., National Pension Service, Aperio Group LLC, Highland Capital Management LLC, Campbell & CO Investment Adviser LLC, Great West Life Assurance Co. Can and IBM Retirement Fund. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $87.32.


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  832 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  1,205
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $112.05 (28.32% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00HighView Rating Details
7/22/2017Barclays PLCReiterated RatingEqual Weight$105.00 -> $100.00LowView Rating Details
7/18/2017Leerink SwannReiterated RatingBuyLowView Rating Details
7/14/2017SunTrust Banks, Inc.Reiterated RatingBuy$115.00LowView Rating Details
7/13/2017BMO Capital MarketsReiterated RatingOutperform$111.00 -> $115.00MediumView Rating Details
7/11/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
5/15/2017Jefferies Group LLCReiterated RatingBuy$116.00N/AView Rating Details
5/8/2017WedbushReiterated RatingHold$108.00LowView Rating Details
5/1/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
4/28/2017Credit Suisse GroupReiterated RatingBuy$116.00LowView Rating Details
4/28/2017Deutsche Bank AGSet Price TargetBuy$103.00 -> $105.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
2/7/2017Morgan StanleyInitiated CoverageOverweight$110.00N/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
11/7/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$105.00 -> $84.00N/AView Rating Details
10/30/2016Royal Bank Of CanadaSet Price TargetBuy$125.00N/AView Rating Details
10/7/2016Goldman Sachs Group, Inc. (The)UpgradeNeutralN/AView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 -> $113.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket Perform$99.00N/AView Rating Details
1/15/2016Bank of America CorporationReiterated RatingBuy$165.00 -> $135.00N/AView Rating Details
10/13/2015Raymond James Financial, Inc.Reiterated RatingOutperform$157.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Earnings History by Quarter for BioMarin Pharmaceutical (NASDAQ BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($0.21)N/AView Earnings Details
5/4/2017Q1 2017($0.30)$0.03$292.58 million$303.70 millionViewListenView Earnings Details
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.13)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.22)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.25)$204.58 million$203.26 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.30)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.42)($0.19)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.50)($0.27)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
2017 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.22)($0.32)
Q2 20174($0.35)($0.17)($0.26)
Q3 20173($0.25)($0.16)($0.22)
Q4 20174($0.34)($0.10)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 96.63%
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/23/2017George Eric DavisEVPSell9,844$96.60$950,930.40View SEC Filing  
6/22/2017Brian MuellerSVPSell2,671$100.00$267,100.00View SEC Filing  
6/19/2017Henry J FuchsInsiderSell15,000$90.00$1,350,000.00View SEC Filing  
6/16/2017V Bryan LawlisDirectorSell3,750$90.00$337,500.00View SEC Filing  
6/7/2017Jeffrey Robert AjerEVPSell1,004$89.61$89,968.44View SEC Filing  
6/5/2017George Eric DavisEVPSell9,471$91.04$862,239.84View SEC Filing  
6/5/2017Jean Jacques BienaimeCEOSell10,000$90.13$901,300.00View SEC Filing  
5/24/2017Jean Jacques BienaimeCEOSell5,000$88.38$441,900.00View SEC Filing  
5/17/2017Jean Jacques BienaimeCEOSell5,000$91.73$458,650.00View SEC Filing  
5/8/2017Brian MuellerSVPSell7,482$91.87$687,371.34View SEC Filing  
5/8/2017Jean Jacques BienaimeCEOSell10,000$96.09$960,900.00View SEC Filing  
5/5/2017George Eric DavisEVPSell2,500$100.34$250,850.00View SEC Filing  
5/2/2017Jeffrey Robert AjerEVPSell302$96.74$29,215.48View SEC Filing  
4/27/2017Jean Jacques BienaimeCEOSell5,000$95.72$478,600.00View SEC Filing  
4/25/2017Jean Jacques BienaimeCEOSell5,000$94.00$470,000.00View SEC Filing  
3/29/2017Jeffrey Robert AjerEVPSell3,890$89.15$346,793.50View SEC Filing  
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.44View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.48View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.00View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.96View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.36View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.00View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.00View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.00View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.87View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioMarin Pharmaceutical (NASDAQ:BMRN)
Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
Source:
DateHeadline
finance.yahoo.com logoCan BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?
finance.yahoo.com - July 27 at 5:08 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:32 AM
finance.yahoo.com logoETFs with exposure to BioMarin Pharmaceutical, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 4:01 PM
americanbankingnews.com logoBioMarin Pharmaceutical's (BMRN) "Equal Weight" Rating Reaffirmed at Barclays PLC
www.americanbankingnews.com - July 22 at 9:28 PM
streetinsider.com logoBioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $100 at Barclays on 2Q US BioPharma Industry Earnings Preview - StreetInsider.com
www.streetinsider.com - July 21 at 5:01 PM
benzinga.com logoFollowing Q2 Beat, Sarepta Has A Key Catalyst Coming In Q4 - Benzinga
www.benzinga.com - July 20 at 6:16 PM
finance.yahoo.com logoSarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why
finance.yahoo.com - July 20 at 6:16 PM
americanbankingnews.com logoFY2018 Earnings Forecast for BioMarin Pharmaceutical Inc. Issued By Leerink Swann (BMRN)
www.americanbankingnews.com - July 20 at 1:46 PM
nasdaq.com logoSarepta & BioMarin Settle Patent Litigation on Exon Skipping - Nasdaq
www.nasdaq.com - July 20 at 6:44 AM
finance.yahoo.com logoSarepta Rockets On Consensus-Crushing Sales, Narrowing Losses
finance.yahoo.com - July 19 at 5:49 PM
finance.yahoo.com logoSarepta & BioMarin Settle Patent Litigation on Exon Skipping
finance.yahoo.com - July 19 at 5:49 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 19 at 12:38 PM
reuters.com logoBRIEF-Sarepta and Biomarin report execution of global settlement
www.reuters.com - July 19 at 4:08 AM
prnewswire.com logoBioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4 ... - PR Newswire (press release)
www.prnewswire.com - July 18 at 11:07 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Receives "Buy" Rating from Leerink Swann
www.americanbankingnews.com - July 18 at 6:42 PM
bizjournals.com logo​BioMarin snags cash as Sarepta skips Duchenne patent battle - San Francisco Business Times
www.bizjournals.com - July 18 at 6:05 PM
finance.yahoo.com logoBioMarin to Host Second Quarter 2017 Financial Results Conference Call and Webcast on Wednesday, August 2 at 4:30pm ET
finance.yahoo.com - July 18 at 6:05 PM
nasdaq.com logoMarket Close Report: NASDAQ Composite index closes at 6314.43 up 1.96 points - Nasdaq
www.nasdaq.com - July 17 at 4:58 PM
americanbankingnews.com logo$309.00 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter
www.americanbankingnews.com - July 15 at 8:19 AM
americanbankingnews.com logoSunTrust Banks, Inc. Reiterates Buy Rating for BioMarin Pharmaceutical Inc. (BMRN)
www.americanbankingnews.com - July 14 at 7:58 PM
finance.yahoo.com logoETFs with exposure to BioMarin Pharmaceutical, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 6:36 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 13 at 2:16 PM
seekingalpha.com logoBiomarin Hemophila A Candidates Looks To Impress The Community - Seeking Alpha
seekingalpha.com - July 13 at 1:35 AM
streetinsider.com logoBioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at BMO Capital; 'BMN 270 Succeeds at Mid & High Doses ... - StreetInsider.com
www.streetinsider.com - July 13 at 1:35 AM
seekingalpha.com logoBioMarin Pharmaceutical (BMRN) Reports Interim Results From Phase 1/2 BMN 270 Clinical Program - Slideshow
seekingalpha.com - July 12 at 5:10 PM
finance.yahoo.com logoBioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : BMRN-US : July 12, 2017
finance.yahoo.com - July 12 at 5:09 PM
streetinsider.com logoBioMarin (BMRN) Announces Positive Phase 1/2 Study Update on BMN 270 for Hemophilia A - StreetInsider.com
www.streetinsider.com - July 11 at 9:58 PM
thestreet.com logoArena Pharma's Stock Could Still Double Even After Tuesday's Epic Run - TheStreet.com
www.thestreet.com - July 11 at 9:58 PM
streetinsider.com logoBioMarin (BMRN) Announces Positive Phase 1/2 Study Update on BMN 270 for Hemophilia A
www.streetinsider.com - July 11 at 4:56 PM
reuters.com logoBRIEF-Biomarin Pharmaceutical says plans to initiate phase 3 registrational study in Q4 2017 for BMN 270
www.reuters.com - July 11 at 4:56 PM
finance.yahoo.com logoBioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year
finance.yahoo.com - July 11 at 4:56 PM
finance.yahoo.com logoCould This Biotech Win In Hemophilia With 'One And Done' Drug?
finance.yahoo.com - July 11 at 4:56 PM
americanbankingnews.com logoBioMarin Pharmaceutical's (NASDAQ:BMRN) "Buy" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - July 11 at 4:10 PM
finance.yahoo.com logoBioMarin Expects These Drugs to Generate Steady Revenues
finance.yahoo.com - July 10 at 9:41 PM
finance.yahoo.com logoWhat to Expect from BioMarin Pharmaceuticals in 2017
finance.yahoo.com - July 8 at 9:20 AM
finance.yahoo.com logoKuvan Could Boost BioMarin’s Revenue Growth in 2017
finance.yahoo.com - July 8 at 9:20 AM
finance.yahoo.com logoA Barrage Of Biotech Updates Expected At ISTH Meeting
finance.yahoo.com - July 8 at 9:20 AM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 2:38 PM
finance.yahoo.com logoBioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
finance.yahoo.com - July 3 at 4:43 PM
streetinsider.com logoBioMarin Pharma (BMRN) Announce the Submission of Pegvaliase Biologics License Application to the U.S. FDA for Treatment of Phenylketonuria
www.streetinsider.com - June 30 at 9:48 PM
reuters.com logoBRIEF-BioMarin submits pegvaliase Biologics License Application to the U.S. FDA for treatment of phenylketonuria
www.reuters.com - June 30 at 9:48 PM
streetinsider.com logoBioMarin Pharma (BMRN) Announce the Submission of Pegvaliase Biologics License Application to the US FDA for ... - StreetInsider.com
www.streetinsider.com - June 30 at 4:44 PM
streetinsider.com logoBioMarin Pharma (BMRN) Announce the Submission of Pegvaliase Biologics License Application to the US FDA for ... - StreetInsider.com
www.streetinsider.com - June 30 at 4:44 PM
finance.yahoo.com logoBioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
finance.yahoo.com - June 30 at 4:44 PM
finance.yahoo.com logoBioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
finance.yahoo.com - June 30 at 4:44 PM
finance.yahoo.com logoBioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : June 28, 2017
finance.yahoo.com - June 28 at 4:40 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) EVP George Eric Davis Sells 9,844 Shares
www.americanbankingnews.com - June 27 at 10:32 PM
finance.yahoo.com logoETFs with exposure to BioMarin Pharmaceutical, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 4:35 PM
finance.yahoo.com logoQuick Tips on Investing in the Pharmaceutical and Medical Device Industry
finance.yahoo.com - June 25 at 9:20 PM
americanbankingnews.com logoComparing BioMarin Pharmaceutical (BMRN) & Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - June 24 at 7:46 AM

Social

Chart

BioMarin Pharmaceutical (BMRN) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff